Evidence for a human humoral immune response to HCV infection providing at least partial protection is accumulating. The observation that antibodies induced to a hypervariable region on HCV E2 envelope protein designated HVR1 have in vitro and in vivo virus neutralization activity indicates that protective antibodies can be elicited. However, antibodies to HVR1 are highly restrictive and are a contributing factor in the development of escape mutants. The primary goal of this project is to develop potent neutralizing human monoclonal antibodies (HMAbs) that could ultimately be used in immunoprophylaxis and potentially for the treatment of HCV infection. We hypothesize that the majority of antibodies with the broadest and most potent activities will recognize conformational epitopes. Preliminary studies indicate that selected individuals with HCV genotype 2a infection are more likely to mount a protective antibody response. It is the intent of this project to focus on the production of HCV-HMAbs to E2 from these selected individuals. More importantly, the recent development of a small animal model for acute HCV infection will permit an eff aboutcient means to test for virus neutralization. A unique irnmunocompromised mouse has been developed capable of sustaining human liver tissues infected with HCV under the renal capsule for up to 26 days. During this period, viral replication occurs as measured by increasing serum viral load. Preliminary studies with three HCV-HMAbs (of which 2 are to conformational epitopes on HCV E2) injected by intraperitoneal route 17-20 days post-transplant of infected tissues significantly reduced HCV viral load in a dose-dependent manner.
The aims of the proposal are to generate HMAbs to HCV E2 protein from peripheral B-cells of individuals infected with genotype 2a; test selected antibodies in a novel human-mouse chimera small animal model for in vivo protection; and determine the breadth of reactivity of these antibodies to divergent HCV isolates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047355-03
Application #
6632274
Study Section
Virology Study Section (VR)
Program Officer
Koshy, Rajen
Project Start
2001-07-15
Project End
2006-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
3
Fiscal Year
2003
Total Cost
$323,050
Indirect Cost
Name
Stanford University
Department
Pathology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Machida, Keigo; Kondo, Yasuteru; Huang, Jeffrey Y et al. (2008) Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol 82:6711-20
Iacob, Roxana E; Keck, Zhenyong; Olson, Oakley et al. (2008) Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein. Biochim Biophys Acta 1784:530-42
Keck, Z Y; Machida, K; Lai, M M C et al. (2008) Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 317:1-38
Owsianka, Ania M; Tarr, Alexander W; Keck, Zhen-Yong et al. (2008) Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89:653-9
Helle, Francois; Goffard, Anne; Morel, Virginie et al. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81:8101-11
Keck, Zhen-Yong; Xia, Jinming; Cai, Zhaohui et al. (2007) Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81:1043-7
Dreux, Marlene; Pietschmann, Thomas; Granier, Christelle et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281:18285-95
Eren, Rachel; Landstein, Dorit; Terkieltaub, Dov et al. (2006) Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80:2654-64
Brazzoli, Michela; Helenius, Ari; Foung, Steven K H et al. (2005) Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 332:438-53
Keck, Zhen-Yong; Li, Ta-Kai; Xia, Jinming et al. (2005) Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol 79:13199-208

Showing the most recent 10 out of 18 publications